Inherited retinal disease
eyeDNA Therapeutics focuses on retinitis pigmentosa, with particular interest in forms linked to PDE6B gene mutations and impaired PDE6β expression.
- Retinitis pigmentosa
- PDE6B-associated retinal degeneration
- Photoreceptor dysfunction
The sponsor’s clinical activity is centered on inherited vision loss and the molecular mechanisms underlying progressive retinal degeneration.
Ocular gene-based therapy
The company is engaged in gene therapy for eye disease, with research interest in restoring retinal function through targeted treatment of the affected gene pathway.
- Subretinal administration
- Ocular gene therapy
- Retinal transduction
This area reflects a strong therapeutic focus on genetically driven retinal disorders that may benefit from localized molecular intervention.
Retinal structure and function
eyeDNA Therapeutics’ research landscape includes the preservation of retinal integrity and visual function in patients with degenerative disease affecting the outer retina.
- Outer retinal degeneration
- Visual function
- Retinal cell preservation
Its clinical interest lies in conditions where loss of retinal cells leads to progressive impairment of night vision and peripheral vision.
